Abstract | PURPOSE: SUBJECTS AND METHODS: RESULTS: The trial in 50 patients in the alendronate group and 52 patients in the raloxifene group could be completed. Both alendronate and raloxifene increased lumbar BMD (+8.0% and +2.4% at 12 months, respectively), followed by reductions of urinary NTX level and serum ALP level; however, the effects of alendronate were more pronounced than those of raloxifene. Only raloxifene reduced the serum levels of TC and LDL-C (-3.9% and -7.7% at 12 months, respectively), without any significant effect on the serum HDL-C and TG levels. CONCLUSION: The present study confirmed the efficacy of alendronate greater than raloxifene in increasing lumbar BMD through its effect on marked reduction of the bone turnover more than by raloxifene, and some beneficial effects of raloxifene on lipid metabolism in elderly women with osteoporosis.
|
Authors | Jun Iwamoto, Yoshihiro Sato, Mitsuyoshi Uzawa, Tsuyoshi Takeda, Hideo Matsumoto |
Journal | Yonsei medical journal
(Yonsei Med J)
Vol. 49
Issue 1
Pg. 119-28
(Feb 29 2008)
ISSN: 0513-5796 [Print] Korea (South) |
PMID | 18306478
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Retracted Publication)
|
Chemical References |
- Biomarkers
- Phosphorus
- Raloxifene Hydrochloride
- Calcium
- Alendronate
|
Topics |
- Aged
- Alendronate
(adverse effects, pharmacology, therapeutic use)
- Biomarkers
(blood)
- Bone Density
(drug effects)
- Calcium
(blood)
- Female
- Fractures, Bone
(prevention & control)
- Humans
- Lipid Metabolism
(drug effects)
- Osteoporosis
(drug therapy, metabolism)
- Phosphorus
(blood)
- Raloxifene Hydrochloride
(adverse effects, pharmacology, therapeutic use)
- Spine
(drug effects)
|